Text Size

PD-1/PD-L1 Pathway Study on Septic Patients

This study has been completed.
Sponsor:
Collaborator:
National Natural Science Foundation of China
Information provided by:
Changhai Hospital
ClinicalTrials.gov Identifier:
NCT01161745
First received: July 13, 2010
Last updated: NA
Last verified: June 2010
History: No changes posted
  Purpose

The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.


Condition
Sepsis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients

Resource links provided by NLM:

MedlinePlus related topics: Sepsis
U.S. FDA Resources

Further study details as provided by Changhai Hospital:

Biospecimen Retention:   Samples Without DNA

peripheral venous blood from septic patients and healthy controls, anticoagulate with EDTA-K2


Enrollment: 39
Study Start Date: December 2008
Study Completion Date: April 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Detailed Description:

First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.

Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.

Then, compare with healthy controls and find the differences.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients who develop sepsis

Criteria

Inclusion Criteria:

  • patients who develop sepsis

Exclusion Criteria:

  • patients with cirrhosis or renal dysfunction
  • patients with dyscrasia
  • patients with autoimmunity diseases
  • patients with severe cardiac and pulmonary diseases
  • patients with hematological diseases
  • patients with diabetes mellitus
  • patients with malignant tumors
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01161745

Sponsors and Collaborators
Changhai Hospital
National Natural Science Foundation of China
Investigators
Principal Investigator: Xiao-ming Deng, doctor Changhai Hospital, the Second Military Medical University
  More Information

No publications provided

Responsible Party: Xiao-ming Deng, Department of Anesthesiology and Intensive Care Unit
ClinicalTrials.gov Identifier: NCT01161745     History of Changes
Other Study ID Numbers: ANETHDEPT-001
Study First Received: July 13, 2010
Last Updated: July 13, 2010
Health Authority: China: Ethics Committee

Keywords provided by Changhai Hospital:
sepsis

Additional relevant MeSH terms:
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013